Loading…

Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020

While smoking is recognized as a risk factor for multiple cardiovascular conditions, prior research has identified a smoker paradox, wherein smokers had better post-procedural outcomes following transcatheter aortic valve replacement (TAVR) in the initial years of its introduction among high-risk pa...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular revascularization medicine 2024-05, Vol.62, p.21-26
Main Authors: Li, Renxi, Luo, Qianyun, Yanavitski, Marat, Huddleston, Stephen J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943
cites cdi_FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943
container_end_page 26
container_issue
container_start_page 21
container_title Cardiovascular revascularization medicine
container_volume 62
creator Li, Renxi
Luo, Qianyun
Yanavitski, Marat
Huddleston, Stephen J
description While smoking is recognized as a risk factor for multiple cardiovascular conditions, prior research has identified a smoker paradox, wherein smokers had better post-procedural outcomes following transcatheter aortic valve replacement (TAVR) in the initial years of its introduction among high-risk patients only. In recent years, TAVR has expanded to significant larger groups of low-risk patients and became the dominate approach for aortic valve replacement. Consequently, the study cohort from the previous research can no longer represent the current patient populations undergoing TAVR. This study aimed to examine the impact of smoking on TAVR outcomes in the later post-TAVR era. Patients who underwent TAVR were identified in the National Inpatient Sample (NIS) database from the last quarter of 2015-2020 by ICD-10-PCS. Patients were stratified into two cohorts based on smoker status. Multivariable analysis was performed comparing in-hospital post-TAVR outcomes. Adjusted pre-procedural variables included sex, age, race, socioeconomic status, comorbidities, and hospital characteristics. A total number of 58,934 patients who underwent TAVR were identified including 23,683 smokers and 35,251 non-smokers. Compared to non-smokers, smokers had lower in-hospital mortality (aOR 0.589, p 
doi_str_mv 10.1016/j.carrev.2023.11.021
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2898957015</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2898957015</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943</originalsourceid><addsrcrecordid>eNo9kEtv1TAQhS0Eog_4Bwh5B5uEGTsPh11VAa1UwaKwtsbOXJFLEgfb94r-e1zdwmqOjuZx5hPiDUKNgN2Hfe0pRj7WCpSuEWtQ-Eyco-lNBYM2z4tuW10ZbYYzcZHSHkD3qutfijNtoFU9Nuci3i_hF8d3SW4UaQx_5LTKHGlNnvJPzhwlhZgnL480H1lG3mbyvPCaP8or-ZXyFFaa5e26FVlceU_LNrOk4j6kKcldDItUgK3MoVQFr8SLHc2JXz_VS_Hj86fv1zfV3bcvt9dXd5XX0OfKo8PyhwPqgM3oWA8KvEejHDejbp3T2o04lDQtjKA1qo4Mtd2OXANDoy_F-9PeLYbfB07ZLlPyPM-0cjgkq8xghrYvyUprc2r1MaQUeWe3OC0UHyyCfaRt9_ZE2z7Stoi20C5jb58uHNzC4_-hf3j1X4wmfRE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2898957015</pqid></control><display><type>article</type><title>Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020</title><source>Elsevier</source><creator>Li, Renxi ; Luo, Qianyun ; Yanavitski, Marat ; Huddleston, Stephen J</creator><creatorcontrib>Li, Renxi ; Luo, Qianyun ; Yanavitski, Marat ; Huddleston, Stephen J</creatorcontrib><description><![CDATA[While smoking is recognized as a risk factor for multiple cardiovascular conditions, prior research has identified a smoker paradox, wherein smokers had better post-procedural outcomes following transcatheter aortic valve replacement (TAVR) in the initial years of its introduction among high-risk patients only. In recent years, TAVR has expanded to significant larger groups of low-risk patients and became the dominate approach for aortic valve replacement. Consequently, the study cohort from the previous research can no longer represent the current patient populations undergoing TAVR. This study aimed to examine the impact of smoking on TAVR outcomes in the later post-TAVR era. Patients who underwent TAVR were identified in the National Inpatient Sample (NIS) database from the last quarter of 2015-2020 by ICD-10-PCS. Patients were stratified into two cohorts based on smoker status. Multivariable analysis was performed comparing in-hospital post-TAVR outcomes. Adjusted pre-procedural variables included sex, age, race, socioeconomic status, comorbidities, and hospital characteristics. A total number of 58,934 patients who underwent TAVR were identified including 23,683 smokers and 35,251 non-smokers. Compared to non-smokers, smokers had lower in-hospital mortality (aOR 0.589, p < 0.01), MACE (aOR 0.678, p < 0.01), MI (aOR 0.719, p < 0.01), stroke (aOR 0.599, p < 0.01), neurological complications (aOR 0.653, p < 0.01), pacemaker implantation (aOR 0.911, p < 0.01), cardiogenic shock (aOR 0.762, p < 0.01), respiratory complications (aOR 0.822, p < 0.01), mechanical ventilation (aOR 0.669, p < 0.01), AKI (aOR 0.745, p < 0.01), VTE (aOR 0.578, p < 0.01), hemorrhage/hematoma (aOR 0.921, p < 0.01), infection (aOR 0.625, p < 0.01), vascular complications (aOR 0.802, p < 0.01), reopen surgery (aOR 0.453), and transfer out to another facility (aOR 0.79, p < 0.01). In addition, cigarette smokers had shorter LOS (p < 0.01), and less hospital charge (p < 0.01). This study identified the smoker paradox in the later post-TAVR era with remarkably broad protection from many complications and lower mortality. The reasons underlying this apparent smoker paradox merit deeper investigation.]]></description><identifier>ISSN: 1553-8389</identifier><identifier>EISSN: 1878-0938</identifier><identifier>DOI: 10.1016/j.carrev.2023.11.021</identifier><identifier>PMID: 38052714</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Aortic Valve - diagnostic imaging ; Aortic Valve - surgery ; Aortic Valve Stenosis - diagnostic imaging ; Aortic Valve Stenosis - mortality ; Aortic Valve Stenosis - surgery ; Databases, Factual ; Female ; Hospital Mortality ; Humans ; Inpatients ; Male ; Non-Smokers ; Postoperative Complications - mortality ; Protective Factors ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Smokers ; Smoking - adverse effects ; Smoking - epidemiology ; Time Factors ; Transcatheter Aortic Valve Replacement - adverse effects ; Transcatheter Aortic Valve Replacement - mortality ; Treatment Outcome ; United States - epidemiology</subject><ispartof>Cardiovascular revascularization medicine, 2024-05, Vol.62, p.21-26</ispartof><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943</citedby><cites>FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38052714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Renxi</creatorcontrib><creatorcontrib>Luo, Qianyun</creatorcontrib><creatorcontrib>Yanavitski, Marat</creatorcontrib><creatorcontrib>Huddleston, Stephen J</creatorcontrib><title>Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020</title><title>Cardiovascular revascularization medicine</title><addtitle>Cardiovasc Revasc Med</addtitle><description><![CDATA[While smoking is recognized as a risk factor for multiple cardiovascular conditions, prior research has identified a smoker paradox, wherein smokers had better post-procedural outcomes following transcatheter aortic valve replacement (TAVR) in the initial years of its introduction among high-risk patients only. In recent years, TAVR has expanded to significant larger groups of low-risk patients and became the dominate approach for aortic valve replacement. Consequently, the study cohort from the previous research can no longer represent the current patient populations undergoing TAVR. This study aimed to examine the impact of smoking on TAVR outcomes in the later post-TAVR era. Patients who underwent TAVR were identified in the National Inpatient Sample (NIS) database from the last quarter of 2015-2020 by ICD-10-PCS. Patients were stratified into two cohorts based on smoker status. Multivariable analysis was performed comparing in-hospital post-TAVR outcomes. Adjusted pre-procedural variables included sex, age, race, socioeconomic status, comorbidities, and hospital characteristics. A total number of 58,934 patients who underwent TAVR were identified including 23,683 smokers and 35,251 non-smokers. Compared to non-smokers, smokers had lower in-hospital mortality (aOR 0.589, p < 0.01), MACE (aOR 0.678, p < 0.01), MI (aOR 0.719, p < 0.01), stroke (aOR 0.599, p < 0.01), neurological complications (aOR 0.653, p < 0.01), pacemaker implantation (aOR 0.911, p < 0.01), cardiogenic shock (aOR 0.762, p < 0.01), respiratory complications (aOR 0.822, p < 0.01), mechanical ventilation (aOR 0.669, p < 0.01), AKI (aOR 0.745, p < 0.01), VTE (aOR 0.578, p < 0.01), hemorrhage/hematoma (aOR 0.921, p < 0.01), infection (aOR 0.625, p < 0.01), vascular complications (aOR 0.802, p < 0.01), reopen surgery (aOR 0.453), and transfer out to another facility (aOR 0.79, p < 0.01). In addition, cigarette smokers had shorter LOS (p < 0.01), and less hospital charge (p < 0.01). This study identified the smoker paradox in the later post-TAVR era with remarkably broad protection from many complications and lower mortality. The reasons underlying this apparent smoker paradox merit deeper investigation.]]></description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aortic Valve - diagnostic imaging</subject><subject>Aortic Valve - surgery</subject><subject>Aortic Valve Stenosis - diagnostic imaging</subject><subject>Aortic Valve Stenosis - mortality</subject><subject>Aortic Valve Stenosis - surgery</subject><subject>Databases, Factual</subject><subject>Female</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Inpatients</subject><subject>Male</subject><subject>Non-Smokers</subject><subject>Postoperative Complications - mortality</subject><subject>Protective Factors</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Smokers</subject><subject>Smoking - adverse effects</subject><subject>Smoking - epidemiology</subject><subject>Time Factors</subject><subject>Transcatheter Aortic Valve Replacement - adverse effects</subject><subject>Transcatheter Aortic Valve Replacement - mortality</subject><subject>Treatment Outcome</subject><subject>United States - epidemiology</subject><issn>1553-8389</issn><issn>1878-0938</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kEtv1TAQhS0Eog_4Bwh5B5uEGTsPh11VAa1UwaKwtsbOXJFLEgfb94r-e1zdwmqOjuZx5hPiDUKNgN2Hfe0pRj7WCpSuEWtQ-Eyco-lNBYM2z4tuW10ZbYYzcZHSHkD3qutfijNtoFU9Nuci3i_hF8d3SW4UaQx_5LTKHGlNnvJPzhwlhZgnL480H1lG3mbyvPCaP8or-ZXyFFaa5e26FVlceU_LNrOk4j6kKcldDItUgK3MoVQFr8SLHc2JXz_VS_Hj86fv1zfV3bcvt9dXd5XX0OfKo8PyhwPqgM3oWA8KvEejHDejbp3T2o04lDQtjKA1qo4Mtd2OXANDoy_F-9PeLYbfB07ZLlPyPM-0cjgkq8xghrYvyUprc2r1MaQUeWe3OC0UHyyCfaRt9_ZE2z7Stoi20C5jb58uHNzC4_-hf3j1X4wmfRE</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Li, Renxi</creator><creator>Luo, Qianyun</creator><creator>Yanavitski, Marat</creator><creator>Huddleston, Stephen J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202405</creationdate><title>Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020</title><author>Li, Renxi ; Luo, Qianyun ; Yanavitski, Marat ; Huddleston, Stephen J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aortic Valve - diagnostic imaging</topic><topic>Aortic Valve - surgery</topic><topic>Aortic Valve Stenosis - diagnostic imaging</topic><topic>Aortic Valve Stenosis - mortality</topic><topic>Aortic Valve Stenosis - surgery</topic><topic>Databases, Factual</topic><topic>Female</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Inpatients</topic><topic>Male</topic><topic>Non-Smokers</topic><topic>Postoperative Complications - mortality</topic><topic>Protective Factors</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Smokers</topic><topic>Smoking - adverse effects</topic><topic>Smoking - epidemiology</topic><topic>Time Factors</topic><topic>Transcatheter Aortic Valve Replacement - adverse effects</topic><topic>Transcatheter Aortic Valve Replacement - mortality</topic><topic>Treatment Outcome</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Renxi</creatorcontrib><creatorcontrib>Luo, Qianyun</creatorcontrib><creatorcontrib>Yanavitski, Marat</creatorcontrib><creatorcontrib>Huddleston, Stephen J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular revascularization medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Renxi</au><au>Luo, Qianyun</au><au>Yanavitski, Marat</au><au>Huddleston, Stephen J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020</atitle><jtitle>Cardiovascular revascularization medicine</jtitle><addtitle>Cardiovasc Revasc Med</addtitle><date>2024-05</date><risdate>2024</risdate><volume>62</volume><spage>21</spage><epage>26</epage><pages>21-26</pages><issn>1553-8389</issn><eissn>1878-0938</eissn><abstract><![CDATA[While smoking is recognized as a risk factor for multiple cardiovascular conditions, prior research has identified a smoker paradox, wherein smokers had better post-procedural outcomes following transcatheter aortic valve replacement (TAVR) in the initial years of its introduction among high-risk patients only. In recent years, TAVR has expanded to significant larger groups of low-risk patients and became the dominate approach for aortic valve replacement. Consequently, the study cohort from the previous research can no longer represent the current patient populations undergoing TAVR. This study aimed to examine the impact of smoking on TAVR outcomes in the later post-TAVR era. Patients who underwent TAVR were identified in the National Inpatient Sample (NIS) database from the last quarter of 2015-2020 by ICD-10-PCS. Patients were stratified into two cohorts based on smoker status. Multivariable analysis was performed comparing in-hospital post-TAVR outcomes. Adjusted pre-procedural variables included sex, age, race, socioeconomic status, comorbidities, and hospital characteristics. A total number of 58,934 patients who underwent TAVR were identified including 23,683 smokers and 35,251 non-smokers. Compared to non-smokers, smokers had lower in-hospital mortality (aOR 0.589, p < 0.01), MACE (aOR 0.678, p < 0.01), MI (aOR 0.719, p < 0.01), stroke (aOR 0.599, p < 0.01), neurological complications (aOR 0.653, p < 0.01), pacemaker implantation (aOR 0.911, p < 0.01), cardiogenic shock (aOR 0.762, p < 0.01), respiratory complications (aOR 0.822, p < 0.01), mechanical ventilation (aOR 0.669, p < 0.01), AKI (aOR 0.745, p < 0.01), VTE (aOR 0.578, p < 0.01), hemorrhage/hematoma (aOR 0.921, p < 0.01), infection (aOR 0.625, p < 0.01), vascular complications (aOR 0.802, p < 0.01), reopen surgery (aOR 0.453), and transfer out to another facility (aOR 0.79, p < 0.01). In addition, cigarette smokers had shorter LOS (p < 0.01), and less hospital charge (p < 0.01). This study identified the smoker paradox in the later post-TAVR era with remarkably broad protection from many complications and lower mortality. The reasons underlying this apparent smoker paradox merit deeper investigation.]]></abstract><cop>United States</cop><pmid>38052714</pmid><doi>10.1016/j.carrev.2023.11.021</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1553-8389
ispartof Cardiovascular revascularization medicine, 2024-05, Vol.62, p.21-26
issn 1553-8389
1878-0938
language eng
recordid cdi_proquest_miscellaneous_2898957015
source Elsevier
subjects Aged
Aged, 80 and over
Aortic Valve - diagnostic imaging
Aortic Valve - surgery
Aortic Valve Stenosis - diagnostic imaging
Aortic Valve Stenosis - mortality
Aortic Valve Stenosis - surgery
Databases, Factual
Female
Hospital Mortality
Humans
Inpatients
Male
Non-Smokers
Postoperative Complications - mortality
Protective Factors
Retrospective Studies
Risk Assessment
Risk Factors
Smokers
Smoking - adverse effects
Smoking - epidemiology
Time Factors
Transcatheter Aortic Valve Replacement - adverse effects
Transcatheter Aortic Valve Replacement - mortality
Treatment Outcome
United States - epidemiology
title Smoker's paradox in transcatheter aortic valve replacement: A National Inpatient Sample analysis from 2015 to 2020
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A04%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Smoker's%20paradox%20in%20transcatheter%20aortic%20valve%20replacement:%20A%20National%20Inpatient%20Sample%20analysis%20from%202015%20to%202020&rft.jtitle=Cardiovascular%20revascularization%20medicine&rft.au=Li,%20Renxi&rft.date=2024-05&rft.volume=62&rft.spage=21&rft.epage=26&rft.pages=21-26&rft.issn=1553-8389&rft.eissn=1878-0938&rft_id=info:doi/10.1016/j.carrev.2023.11.021&rft_dat=%3Cproquest_cross%3E2898957015%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c307t-c1b1093b0a60e8dbe3920cc182be4d35bb33bd19ace50d033126a8a56fab40943%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2898957015&rft_id=info:pmid/38052714&rfr_iscdi=true